the treatment of low and high-risk polycythemia vera
Published 2 years ago • 1.9K plays • Length 3:39Download video MP4
Download video MP3
Similar videos
-
3:07
the current treatment algorithm for polycythemia vera
-
2:16
ropeginterferon vs standard therapy for polycythemia vera
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
2:14
risk-adapted treatment of et & pv
-
11:33
treatment algorithm for low-risk mds
-
10:56
identifying and communicating your polycythemia vera (pv) symptoms
-
12:06
can patients with polycythemia vera (pv) live a normal lifespan?
-
5:34
understanding how polycythemia vera (pv) may change over time
-
3:59
pv: outcomes, unmet needs, and therapeutic strategies
-
1:02
update on treatments for high- and low-risk mds
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:18
the epidemiology and treatment of chronic gvhd post-allosct
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
1:37
a prospective trial of radiation-free chemotherapy in high- and low-risk hl
-
1:33
novel treatments for cold agglutinin disease
-
2:04
state-of-the-art treatment for hr-mds
-
1:52
cytoreductive therapy for patients with pv
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
3:15
updates on ropeginterferon in pv
-
2:11
new therapeutic options for low-risk mds
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl